PURPOSE: To compare outcomes of patients treated with low-dose-rate (LDR) adjuvant brachytherapy (BT) + external beam radiation therapy (EBRT) vs. high-dose-rate (HDR) adjuvant BT + EBRT. METHODS AND MATERIALS: Thirty-seven patients with soft tissue sarcoma (STS) were treated with pre- or postoperative external beam irradiation and postoperative LDR or HDR BT. RESULTS: There was no significant difference in the 2-year local control rates (90% with LDR boost vs. 94% for HDR). The rate of National Cancer Institute (NCI) grades 2-4 wound-healing complications was 40% in the LDR group vs. 18% in the HDR group (p = 0.14). On univariate analysis, only suboptimal geometry of the implant predicted for increasing complication rate in the LDR group. In the HDR group, BT dose per fraction, total BT dose, and total biologically equivalent dose (BED3) radiation dose were significant. CONCLUSIONS: HDR and LDR boost BT results in acceptable local control for STS. There is a suggestion that HDR may have lower incidence of severe (grade > or = 3) acute toxicity than LDR.
PURPOSE: To compare outcomes of patients treated with low-dose-rate (LDR) adjuvant brachytherapy (BT) + external beam radiation therapy (EBRT) vs. high-dose-rate (HDR) adjuvant BT + EBRT. METHODS AND MATERIALS: Thirty-seven patients with soft tissue sarcoma (STS) were treated with pre- or postoperative external beam irradiation and postoperative LDR or HDR BT. RESULTS: There was no significant difference in the 2-year local control rates (90% with LDR boost vs. 94% for HDR). The rate of National Cancer Institute (NCI) grades 2-4 wound-healing complications was 40% in the LDR group vs. 18% in the HDR group (p = 0.14). On univariate analysis, only suboptimal geometry of the implant predicted for increasing complication rate in the LDR group. In the HDR group, BT dose per fraction, total BT dose, and total biologically equivalent dose (BED3) radiation dose were significant. CONCLUSIONS: HDR and LDR boost BT results in acceptable local control for STS. There is a suggestion that HDR may have lower incidence of severe (grade > or = 3) acute toxicity than LDR.
Authors: Jason Klein; Alex Ghasem; Samuel Huntley; Nathan Donaldson; Martin Keisch; Sheila Conway Journal: Clin Orthop Relat Res Date: 2018-03 Impact factor: 4.176
Authors: Julie A Bradley; Sara H Kleinman; Jason Rownd; David King; Donald Hackbarth; Robert Whitfield; Dian Wang Journal: J Contemp Brachytherapy Date: 2011-03-31
Authors: Annalisa Cortesi; Andrea Galuppi; Rezarta Frakulli; Alessandra Arcelli; Fabrizio Romani; Gian Carlo Mattiucci; Giuseppe Bianchi; Stefano Ferrari; Andrea Ferraro; Andrea Farioli; Marco Gambarotti; Alberto Righi; Gabriella Macchia; Francesco Deodato; Savino Cilla; Milly Buwenge; Vincenzo Valentini; Alessio Giuseppe Morganti; Davide Donati; Silvia Cammelli Journal: J Contemp Brachytherapy Date: 2017-06-05
Authors: Cameron M Callaghan; M M Hasibuzzaman; Samuel N Rodman; Jessica E Goetz; Kranti A Mapuskar; Michael S Petronek; Emily J Steinbach; Benjamin J Miller; Casey F Pulliam; Mitchell C Coleman; Varun V Monga; Mohammed M Milhem; Douglas R Spitz; Bryan G Allen Journal: Cancers (Basel) Date: 2020-08-12 Impact factor: 6.639